规格: | 98% |
分子量: | 2311.62 |
包装 | 价格(元) |
500ug | 电议 |
1mg | 电议 |
5mg | 电议 |
Background:
C-Type Natriuretic Peptide (CNP) (1-22), human TFA, exerts its main biological effects by binding to natriuretic peptide receptor B (NPR-B), a membrane-bound guanylyl cyclase receptor that produces cyclic guanosine monophosphate (cGMP). C-Type Natriuretic Peptide (CNP) is a selective agonist of natriuretic peptide receptors NPR-B and C (Kds = 7, and 10.8 pM)[1].
C-Type Natriuretic Peptide (CNP) (1-22), significantly promoted longitudinal bone growth in an organ culture experiment using tibiae from fetal mice[2]. C-Type Natriuretic Peptide (CNP) (1-22) in vivo administration might attenuate cardiac remodeling after myocardial infarction (MI) through its antifibrotic and antihypertrophic action[3]. NPR-B-mediated cGMP production after CNP administration specifically acted on the pylorus, colon, and rectum and contributed to gastric emptying[1].
参考文献:
[1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9.
[2]. Yasoda A, Ogawa Y, Suda M, Tamura N, Mori K, Sakuma Y, Chusho H, Shiota K, Tanaka K, Nakao K (1998) Natriuretic peptide regulation of endochondral ossification. Evidence for possible roles of the C-type natriuretic peptide/guanylyl cyclase-B pathway. J Biol Chem 273:11 695-11 700
[3]. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K. C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. 2005.J Am Coll Cardiol 45:608-616
Protocol:
Animal experiment [2]: | |
Animal models | Four-week-old female ddY mice |
Preparation Method | Mice were separated into four groups: the untreated (baseline) group, the 2 mg/kg C-Type Natriuretic Peptide (CNP) group, the 1 mg/kg C-Type Natriuretic Peptide (CNP) group, and the vehicle (normal saline) group. C-Type Natriuretic Peptide (CNP) and vehicle were administered intravenously. |
Dosage form | Intravenously injection, 1 or 2 mg/kg |
Applications | In the pylorus and rectum, after 2 mg/kg C-Type Natriuretic Peptide (CNP) was administered, cGMP production was remarkably increased as early as 1 minute compared with that after 1 mg/kg C-Type Natriuretic Peptide (CNP) was administered |
参考文献: [1]: Sogawa C, Wakizaka H, Aung W, Jin ZH, Tsuji AB, Furukawa T, et al. C-type natriuretic peptide specifically acts on the pylorus and large intestine in mouse gastrointestinal tract. Am J Pathol. 2013;182:172-9. |